|1.||Rubinsztein, David C: 8 articles (10/2015 - 04/2003)|
|2.||Lyles, Douglas S: 8 articles (04/2014 - 12/2004)|
|3.||Sakai, Norio: 7 articles (01/2014 - 08/2005)|
|4.||Adachi, Naoko: 7 articles (01/2014 - 08/2005)|
|5.||Seki, Takahiro: 7 articles (01/2014 - 08/2005)|
|6.||Saito, Naoaki: 7 articles (01/2014 - 08/2005)|
|7.||Borchelt, David R: 6 articles (05/2015 - 04/2007)|
|8.||Sarkar, Sovan: 5 articles (10/2013 - 04/2006)|
|9.||Zoghbi, Huda Y: 4 articles (03/2015 - 07/2009)|
|10.||Orr, Harry T: 4 articles (03/2015 - 07/2009)|
|1.||Neurodegenerative Diseases (Neurodegenerative Disease)
05/01/2012 - "Although currently there is no effective cure to prevent or slow down the progression of these neurodegenerative disorders, increasing the clearance of mutant proteins has been proposed as a potential therapeutic approach. "
01/01/2013 - "Emerging evidence indicates important protective roles being played by autophagy in neurodegenerative disorders through clearance of aggregate-prone or mutant proteins. "
01/01/2013 - "Therefore, findings in the current study provide detailed insights into the protective mechanism of a novel autophagy inducer, which is valuable for further investigation as a new candidate agent for modulating neurodegenerative disorders through the reduction of toxicity and clearance of mutant proteins in the cellular level."
04/01/2010 - "Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases."
04/09/2010 - "Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases."
05/01/2012 - "An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity."
09/15/2013 - "Despite the prospect of treating AML and other cancers by targeting IDH mutant proteins, it remains unclear how these mutants affect tumor development and maintenance in vivo, and no cancer models exist to study the action of IDH2 mutants in vivo. "
01/01/2010 - "To better understand the role of p27 in tumor predisposition and to characterize the MENX animal model at the molecular level, a prerequisite for future preclinical studies, we set out to assess the functional properties of the MENX-associated p27 mutant protein (named p27fs177) in vitro and in vivo. "
03/12/1999 - "However, the study of mutant proteins identified in tumors that do not form tetramers has shown that they have lost the wild-type activity like most of the p53 DBD mutants. "
02/28/1999 - "Over the period of the last three to five years, studies of the specific mutations responsible for these syndromes and the cellular signaling pathways disrupted by the mutant proteins have begun to provide unprecedented insights into the molecular origin and pathogenesis of inherited and sporadic forms of cancer. "
|3.||Huntington Disease (Huntington's Disease)
09/01/2008 - "We also report the growing list of new drugs/pathways that upregulate autophagy to enhance the clearance of this mutant protein, as autophagy upregulation may be a tractable strategy for the treatment of Huntington's disease."
01/01/2015 - "This study increases our understanding of the effects of Huntington's disease on peripheral tissues, while further demonstrating the differential effects of the mutant protein on different but related cell types. "
07/01/2014 - "Huntington disease (HD) is caused by a genetically encoded pathological protein (mutant huntingtin [mHtt]), which is thought to exert its effects in a cell-autonomous manner. "
01/01/2014 - "The autosomal dominant inheritance pattern of Huntington's disease suggests the importance of the mutant protein, huntingtin, in pathogenesis of Huntington's disease, but wild type huntingtin also has been shown to be important for neuronal functions such as axonal transport. "
02/01/2012 - "The most robust suppressors reduced both soluble and aggregated Huntingtin levels, suggesting toxicity is likely to be associated with both forms of the mutant protein in Huntington's disease."
|4.||Cystic Fibrosis (Mucoviscidosis)
12/01/2015 - "There are nearly 2000 mutations in the CFTR gene associated with cystic fibrosis disease, and to date, the only approved drug, Kalydeco, has been effective in rescuing the functional expression of a small subset of these mutant proteins with defects in channel activation. "
11/01/2010 - "An improved understanding of the molecular mechanisms underlying the basic genetic defect in cystic fibrosis have led to new treatment strategies to repair the mutant protein."
04/01/2011 - "We analyse a paper, which reports an entirely novel approach to the treatment of cystic fibrosis, consisting in "repairing" the defective mutant protein. "
01/01/2003 - "Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism."
11/01/2001 - "A number of genetic diseases, including cystic fibrosis, have been identified as disorders of protein trafficking associated with retention of mutant protein within the endoplasmic reticulum. "
|5.||Renal Tubular Acidosis (Distal Renal Tubular Acidosis)
03/01/2002 - "The article discusses a likely mechanism for dominant distal renal tubular acidosis in which associations between the normal and mutant protein alter the plasma membrane targeting of the normal protein in the kidney."
06/01/2005 - "In vitro functional studies of these mutant proteins in cell expression systems have helped to elucidate the molecular mechanisms underlying renal tubular acidosis, which ultimately may lead to new therapeutic options in what is still treatment only by giving an oral alkali."
01/01/2013 - "Mutations in the SLC4A1 gene encoding the anion exchanger 1 (AE1) can cause distal renal tubular acidosis (dRTA), a disease often due to mis-trafficking of the mutant protein. "
|1.||Proteasome Endopeptidase Complex (Proteasome)
|6.||RNA (Ribonucleic Acid)
|7.||GTP-Binding Proteins (G-Protein)
|10.||Proteins (Proteins, Gene)
|1.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)